<DOC>
	<DOCNO>NCT00844545</DOCNO>
	<brief_summary>The purpose study determine whether eculizumab safe effective treatment adult patient plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome ( aHUS ) .</brief_summary>
	<brief_title>Open Label Controlled Trial Eculizumab Adult Patients With Plasma Therapy-Resistant aHUS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>1 . TTP , ( defined ADAMTS13 activity &lt; 5 % ) historical observation ( prior initiation plasma therapy ) test screen visit central laboratory 2 . Malignancy within 5 year screen 3 . Typical HUS ( Shiga toxin + ) 4 . Known HIV infection 5 . Identified drug exposurerelated HUS . 6 . Infectionrelated HUS 7 . HUS relate bone marrow transplant 8 . HUS related vitamin B12 deficiency 9 . Renal function status require chronic dialysis 10 . Patients confirm diagnosis sepsis 11 . Presence suspicion active untreated systemic bacterial infection , opinion Investigator confound accurate diagnosis aHUS impedes ability manage aHUS disease 12 . Pregnancy lactation 13 . Unresolved meningococcal disease 14 . Known Systemic Lupus Erythematosus ( SLE ) antiphospholipid antibody positivity syndrome 15 . Any medical psychological condition , opinion investigator , could increase patient 's risk participate study confound outcome study 16 . Patients receive previous treatment eculizumab 17 . Patients receive IVIG within 8 week Rituximab therapy within 12 week screen . 18 . Patients receive immunosuppressive therapy steroid , mTOR inhibitor tacrolimus exclude unless : [ 1 ] part establish posttransplant antirejection regime , [ 2 ] patient confirm antiCFH antibody require immunosuppressive therapy , [ 3 ] dose medication unchanged least 4 week prior screen period [ 4 ] patient experience acute aHUS relapse immediately transplant 19 . Patients receive Erythrocyte Stimulating Agents ( ESAs ) unless already stable dose least 4 week prior screen period , washout period least 2 week last dose ESA therapy . 20 . Participation investigational drug trial exposure investigational agent , device , procedures begin 4 week prior screen throughout entire trial . 21 . Hypersensitivity eculizumab , murine proteins one excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>aHUS</keyword>
</DOC>